Ceforanide and cefazolin therapy of pneumonia: comparative clinical trial.

Antimicrobial Agents and Chemotherapy
R J WallaceS B Greenberg

Abstract

Ceforanide is a new (parenteral) long-acting cephalosporin with antimicrobial activity comparable to those of other second-generation cephalosporins. In a randomized prospective study, patients with community-acquired bacterial pneumonia were treated with ceforanide at 0.5 g every 12 h (28 cases) or with cefazolin at 1.0 g every 8 h (26 cases). The study groups were comparable in clinical and laboratory findings, including etiological diagnosis. Streptococcus pneumoniae was isolated from the sputum of 38 patients, of whom 8 (21%) were bacteremic. Mean peak and trough serum levels of ceforanide drawn 1 and 11.5 h after the 0.5-g intravenous dose were 39.6 and 2.5 microgram/ml, respectively. Of the 50 patients evaluable for efficacy, all responded clinically with no serious adverse reactions. In spite of clinical improvement and in vitro susceptibility, Haemophilus influenzae persisted in the sputum of five of the eight cefazolin-treated patients and four of the five patients treated with ceforanide. Ceforanide appears to be as safe and effective as cefazolin for the therapy of pneumonia caused by S. pneumoniae or H. influenzae, but neither drug was effective in clearing H. influenzae from the sputum.

References

Oct 5, 1978·The New England Journal of Medicine·M R JacobsR Austrian
Jul 1, 1978·Antimicrobial Agents and Chemotherapy·B G PettyP S Lietman
Nov 1, 1978·Annals of Internal Medicine·R Quintiliani, C H Nightingale
Aug 1, 1975·The American Journal of Medicine·G A WongP D Hoeprich
Jan 28, 1971·The New England Journal of Medicine·D HansmanR Douglas
Mar 1, 1973·Annals of Internal Medicine·R J MangiV T Andriole
Jan 1, 1981·Antimicrobial Agents and Chemotherapy·W S NgK Arnold
Feb 1, 1980·Antimicrobial Agents and Chemotherapy·F H LeeG H Hottendorf
May 1, 1964·Annals of Internal Medicine·R AUSTRIAN, J GOLD

❮ Previous
Next ❯

Citations

Nov 20, 2001·Thorax·UNKNOWN British Thoracic Society Standards of Care Committee
Nov 1, 1982·Pharmacotherapy·S L Barriere, J Mills
Mar 1, 1985·Drug Intelligence & Clinical Pharmacy·T A Tartaglione, R E Polk
Sep 1, 1983·Drug Intelligence & Clinical Pharmacy·P GarzoneV L Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.